Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Диагностика хронического легочного сердца в практике лечащего врача - Справочник поликлинического врача №3 (2018)
Диагностика хронического легочного сердца в практике лечащего врача
Барт Б.Я., Ларина В.Н., Вартанян Е.А. и др. Диагностика хронического легочного сердца в практике лечащего врача. Справочник поликлинического врача. 2018; 3: 31–38.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассматриваются современные аспекты классификации и диагностики хронического легочного сердца и легочной гипертензии. Подробно рассматриваются гемодинамические параметры малого круга кровообращения в диагностике различных видов прекапиллярной легочной гипертензии.
Ключевые слова: хроническое легочное сердце, прекапиллярная легочная гипертензия, классификация легочной гипертензии, диагностика легочной гипертензии.
Key words: сhronic cor pulmonale, precapillary pulmonary hypertension, classification of pulmonary hypertension, diagnosis of pulmonary hypertension.
Ключевые слова: хроническое легочное сердце, прекапиллярная легочная гипертензия, классификация легочной гипертензии, диагностика легочной гипертензии.
________________________________________________
Key words: сhronic cor pulmonale, precapillary pulmonary hypertension, classification of pulmonary hypertension, diagnosis of pulmonary hypertension.
Полный текст
Список литературы
1. Tapson VF, Humbert M. Incidence and Prevalens of Chronic Thromboembolic Pulmonary Hypertension. Proc Am Thorac Soc 2006; 3: 564–7.
2. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (2): 164–72.
3. Pulido T, Adzerikho I, Channick RN et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809–18.
4. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013, 62: D109–116.
5. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67–119.
6. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41: 217–23.
7. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): D34–D41.
8. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109–116.
9. Simonneau G, D'Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–302.
10. Ghofrani H-A, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
11. Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: D92–99.
12. Galiè N, Humbert M, Vachiery J-L et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–75.
13. Van de Veerdonk MC, Marcus JT, Westerhof N et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015; 147: 1063–71.
14. Hsu S, Houston BA, Tampakakis E et al. Right ventricular functional reserve in pulmonary arterial hypertension. Circulation 2016; 133: 2413–22.
15. Tedford RJ, Mudd JO, Girgis RE et al. Right ventricular dysfunction in systemic sclerosis‐associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6: 953–63.
16. Brewis MJ, Bellofiore A, Vanderpool RR et al. Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. Int J Cardiol 2016; 218: 206–11.
17. Khan SS, Cuttica MJ, Beussink-Nelson L et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ 2015; 5: 547–56.
18. Spruijt OA, de Man FS, Groepenhoff H et al. The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension. Am J Respir Crit Care Med 2015; 191: 1050–7.
19. Reesink HJ, Marcus JT, Tulevski II et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 2007; 133: 58–64.
20. Vonk Noordegraaf A, Westerhof N. Right ventricular ejection fraction and NT-proBNP are both indicators of wall stress in pulmonary hypertension. Eur Respir J 2007; 29: 622–3.
21. Mauritz G-J, Rizopoulos D, Groepenhoff H et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645–50.
2. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (2): 164–72.
3. Pulido T, Adzerikho I, Channick RN et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809–18.
4. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013, 62: D109–116.
5. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67–119.
6. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41: 217–23.
7. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): D34–D41.
8. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109–116.
9. Simonneau G, D'Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–302.
10. Ghofrani H-A, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
11. Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: D92–99.
12. Galiè N, Humbert M, Vachiery J-L et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–75.
13. Van de Veerdonk MC, Marcus JT, Westerhof N et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015; 147: 1063–71.
14. Hsu S, Houston BA, Tampakakis E et al. Right ventricular functional reserve in pulmonary arterial hypertension. Circulation 2016; 133: 2413–22.
15. Tedford RJ, Mudd JO, Girgis RE et al. Right ventricular dysfunction in systemic sclerosis‐associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6: 953–63.
16. Brewis MJ, Bellofiore A, Vanderpool RR et al. Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. Int J Cardiol 2016; 218: 206–11.
17. Khan SS, Cuttica MJ, Beussink-Nelson L et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ 2015; 5: 547–56.
18. Spruijt OA, de Man FS, Groepenhoff H et al. The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension. Am J Respir Crit Care Med 2015; 191: 1050–7.
19. Reesink HJ, Marcus JT, Tulevski II et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 2007; 133: 58–64.
20. Vonk Noordegraaf A, Westerhof N. Right ventricular ejection fraction and NT-proBNP are both indicators of wall stress in pulmonary hypertension. Eur Respir J 2007; 29: 622–3.
21. Mauritz G-J, Rizopoulos D, Groepenhoff H et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645–50.
2. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (2): 164–72.
3. Pulido T, Adzerikho I, Channick RN et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809–18.
4. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013, 62: D109–116.
5. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67–119.
6. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41: 217–23.
7. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): D34–D41.
8. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109–116.
9. Simonneau G, D'Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–302.
10. Ghofrani H-A, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
11. Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: D92–99.
12. Galiè N, Humbert M, Vachiery J-L et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–75.
13. Van de Veerdonk MC, Marcus JT, Westerhof N et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015; 147: 1063–71.
14. Hsu S, Houston BA, Tampakakis E et al. Right ventricular functional reserve in pulmonary arterial hypertension. Circulation 2016; 133: 2413–22.
15. Tedford RJ, Mudd JO, Girgis RE et al. Right ventricular dysfunction in systemic sclerosis‐associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6: 953–63.
16. Brewis MJ, Bellofiore A, Vanderpool RR et al. Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. Int J Cardiol 2016; 218: 206–11.
17. Khan SS, Cuttica MJ, Beussink-Nelson L et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ 2015; 5: 547–56.
18. Spruijt OA, de Man FS, Groepenhoff H et al. The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension. Am J Respir Crit Care Med 2015; 191: 1050–7.
19. Reesink HJ, Marcus JT, Tulevski II et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 2007; 133: 58–64.
20. Vonk Noordegraaf A, Westerhof N. Right ventricular ejection fraction and NT-proBNP are both indicators of wall stress in pulmonary hypertension. Eur Respir J 2007; 29: 622–3.
21. Mauritz G-J, Rizopoulos D, Groepenhoff H et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645–50.
________________________________________________
2. Benza RL, Miller DP, Gomberg-Maitland M et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation 2010; 122 (2): 164–72.
3. Pulido T, Adzerikho I, Channick RN et al. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension. N Engl J Med 2013; 369: 809–18.
4. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013, 62: D109–116.
5. Galiè N, Humbert M, Vachiery JL et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 2016; 37 (1): 67–119.
6. Naeije R, Vachiery JL, Yerly P, Vanderpool R. The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease. Eur Respir J 2013; 41: 217–23.
7. Simonneau G, Gatzoulis MA, Adatia I et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62 (Suppl. 25): D34–D41.
8. Seeger W, Adir Y, Barbera JA et al. Pulmonary hypertension in chronic lung diseases. J Am Coll Cardiol 2013; 62: D109–116.
9. Simonneau G, D'Armini AM, Ghofrani H-A et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2). Eur Respir J 2015; 45: 1293–302.
10. Ghofrani H-A, D'Armini AM, Grimminger F et al. Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. N Engl J Med 2013; 369: 319–29.
11. Kim NH, Delcroix M, Jenkins DP et al. Chronic thromboembolic pulmonary hypertension. J Am Coll Cardiol 2013; 62: D92–99.
12. Galiè N, Humbert M, Vachiery J-L et al. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2015; 46: 903–75.
13. Van de Veerdonk MC, Marcus JT, Westerhof N et al. Signs of right ventricular deterioration in clinically stable patients with pulmonary arterial hypertension. Chest 2015; 147: 1063–71.
14. Hsu S, Houston BA, Tampakakis E et al. Right ventricular functional reserve in pulmonary arterial hypertension. Circulation 2016; 133: 2413–22.
15. Tedford RJ, Mudd JO, Girgis RE et al. Right ventricular dysfunction in systemic sclerosis‐associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6: 953–63.
16. Brewis MJ, Bellofiore A, Vanderpool RR et al. Imaging right ventricular function to predict outcome in pulmonary arterial hypertension. Int J Cardiol 2016; 218: 206–11.
17. Khan SS, Cuttica MJ, Beussink-Nelson L et al. Effects of ranolazine on exercise capacity, right ventricular indices, and hemodynamic characteristics in pulmonary arterial hypertension: a pilot study. Pulm Circ 2015; 5: 547–56.
18. Spruijt OA, de Man FS, Groepenhoff H et al. The effects of exercise on right ventricular contractility and right ventricular-arterial coupling in pulmonary hypertension. Am J Respir Crit Care Med 2015; 191: 1050–7.
19. Reesink HJ, Marcus JT, Tulevski II et al. Reverse right ventricular remodeling after pulmonary endarterectomy in patients with chronic thromboembolic pulmonary hypertension: utility of magnetic resonance imaging to demonstrate restoration of the right ventricle. J Thorac Cardiovasc Surg 2007; 133: 58–64.
20. Vonk Noordegraaf A, Westerhof N. Right ventricular ejection fraction and NT-proBNP are both indicators of wall stress in pulmonary hypertension. Eur Respir J 2007; 29: 622–3.
21. Mauritz G-J, Rizopoulos D, Groepenhoff H et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645–50.
Авторы
Б.Я.Барт*, В.Н.Ларина, Е.А.Вартанян, М.Г.Головко, В.Ф.Беневская, М.П.Михайлусова
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*Medicalmail@rambler.ru
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*Medicalmail@rambler.ru
ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н.И.Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1
*Medicalmail@rambler.ru
________________________________________________
N.I.Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation. 117997, Russian Federation, Moscow, ul. Ostrovitianova, d. 1
*Medicalmail@rambler.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.